‘Public Health Crisis’ Warning For Northern Ireland Over Post-Brexit Guidance
Confusion Reigns Over Location Of MAHs and QPPVs
Executive Summary
With the likelihood of a UK-EU trade deal still in the balance, the UK life sciences industry has called for clarification from UK and EU regulators regarding the regulatory situation in Northern Ireland from next year.
You may also be interested in...
UK Industry Chief Insists On Need For More Clarity On Medicines Regulation
The post-Brexit agreement between the UK and the EU leaves some grey areas in the field of medicines regulation. The UK government is coming under pressure to clarify the situation.
Life Science Sector Still In The Dark As UK-EU Trade Talks Make Progress
Hope is not lost as the EU sees a "narrow path" to a trade deal with the UK, but the life sciences industry is still facing uncertainty over key issues such as medicines batch testing.
Industry Gets Breathing Space For Post-Brexit Regulation In Northern Ireland
The pharmaceutical industry has welcomed a decision to allow more time to bring in new medicines regulations in Northern Ireland, but continues to insist that a mutual recognition agreement between the UK and the EU on drug manufacturing is the best way forward.